Article thumbnail
Location of Repository

The pharmaceutical industry and access and benefit-sharing

By Florian Kern

Abstract

My contribution is based on an analysis of the voluntary realisation of the Access and Benfit-Sharing (ABS) stipulations of the UN Convention on Biological Diversity (CBD) by the pharmaceutical industry. Our research shows that on a voluntary basis the pharmaceutical industry realises ABS provisions of the CBD only to a very limited extent. We thus argue for the necessity of an legally binding ABS protocol on the basis of the Bonn guidelines

Publisher: Federal Agency for Nature Conservation, Germany
Year: 2007
OAI identifier: oai:sro.sussex.ac.uk:26674
Sorry, our data provider has not provided any external links therefore we are unable to provide a link to the full text.

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.